爾康製藥(300267.SZ):完成轉讓粵爾康95%股權
格隆匯 9 月 24日丨爾康製藥(300267.SZ)公佈,公司於2020年8月27日召開第四屆董事會第九次會議、第四屆監事會第九次會議,審議通過了《關於轉讓全資子公司股權的議案》,同意公司與自然人黃樹標、蕭慶廣、伍凱建、黃翎綱簽署《股權收購協議》,上述四位自然人以人民幣約1.01億元收購公司全資子公司廣東粵爾康製藥有限公司(“粵爾康”)95%股權。
截至公告披露日,公司已按《股權收購協議》約定收到上述股權轉讓的全部款項,粵爾康也已完成工商變更登記並取得更新後的營業執照。此次交易完成後,公司仍持有粵爾康5%股權,粵爾康不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.